SCOPUS 정보 검색 플랫폼

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 12, Issue 3, 2012, Pages 247-249

Value for money of drug regulation

(3) Bouvy, Jacoline C a,b Koopmanschap, Marc A b Schellekens, Huub a,c

a UTRECHT UNIVERSITY (Netherlands)

b ERASMUS UNIVERSITY ROTTERDAM (Netherlands)

c UTRECHT UNIVERSITY (Netherlands)

Author keywords

cost effectiveness analysis; drug regulation; economic evaluation

Indexed keywords

RECOMBINANT ERYTHROPOIETIN; ROFECOXIB; TGN 1412;

COST EFFECTIVENESS ANALYSIS; DRUG CONTROL; DRUG COST; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; ERYTHROCYTE APLASIA; HEALTH INSURANCE; HEALTH PROMOTION; HEART INFARCTION; HUMAN; LIFE EXPECTANCY; MONEY; PHARMACEUTICAL CARE; POSTMARKETING SURVEILLANCE; QT INTERVAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; REVIEW; STROKE; UNSPECIFIED SIDE EFFECT;

COST-BENEFIT ANALYSIS; DRUG AND NARCOTIC CONTROL; DRUG DESIGN; DRUG INDUSTRY; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 84864216427 PISSN: 14737167 EISSN: 17448379 Source Type: Journal
DOI: 10.1586/erp.12.18 Document Type: Review

Times cited : (4)

References (8)

1
- 0012791005
- WHO, Geneva, Switzerland
- Ratanawijitrasin S, Wondemagegnehu E Effective Drug Regulation: A Multicountry Study. WHO, Geneva, Switzerland (2002
- (2002) Wondemagegnehu Effective Drug Regulation: A Multicountry Study
- Ratanawijitrasin, S.¹

2
- 73449101512
- Lessons from 60 years of pharmaceutical innovation
- Munos B. Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 8(12), 959-968 (2009
- (2009) Nat. Rev. Drug Discov. , vol.8 , Issue.12 , pp. 959-968
- Munos, B.¹

3
- 84857743319
- Diagnosing the decline in pharmaceutical R&D efficiency
- Scannell JW, Blanckley A, Boldon H, Warrington B. Diagnosing the decline in pharmaceutical R&D efficiency. Nat. Rev. Drug Discov. 11(3), 191-200 (2012
- (2012) Nat. Rev. Drug Discov. , vol.11 , Issue.3 , pp. 191-200
- Scannell, J.W.¹ Blanckley, A.² Boldon, H.³ Warrington, B.⁴

4
- 40249101607
- First do no harm improving drug safety through legislation and independent research
- Greener M. First do no harm. Improving drug safety through legislation and independent research. EMBO Rep. 9(3), 221-224 (2008
- (2008) EMBO Rep. , vol.9 , Issue.3 , pp. 221-224
- Greener, M.¹

5
- 37349089029
- First-in-Man (FIM) clinical trials post-tegenero: A review of the impact of the TeGenero trial on the design, conduct, and ethics of FIM trials
- Nada A, Somberg J. First-in-Man (FIM) clinical trials post-TeGenero: A review of the impact of the TeGenero trial on the design, conduct, and ethics of FIM trials. Am. J. Ther. 14(6), 594-604 (2007
- (2007) Am. J. Ther. , vol.14 , Issue.6 , pp. 594-604
- Nada, A.¹ Somberg, J.²

6
- 33749027737
- Can pharmacogenetics help rescue drugs withdrawn from the market
- Shah RR. Can pharmacogenetics help rescue drugs withdrawn from the market? Pharmacogenomics 7(6), 889-908 (2006
- (2006) Pharmacogenomics , vol.7 , Issue.6 , pp. 889-908
- Shah, R.R.¹

7
- 84855965809
- The cost-effectiveness of drug regulation: The example of thorough QT/QTc studies
- Bouvy JC, Koopmanschap MA, Shah RR, Schellekens H. The cost-effectiveness of drug regulation: The example of thorough QT/QTc studies. Clin. Pharmacol. Ther 91(2), 281-288 (2012
- (2012) Clin. Pharmacol. Ther , vol.91 , Issue.2 , pp. 281-288
- Bouvy, J.C.¹ Koopmanschap, M.A.² Shah, R.R.³ Schellekens, H.⁴

8
- 80054093763
- Willingness to pay for adverse drug event regulatory actions
- Bouvy J, Weemers J, Schellekens H, Koopmanschap M. Willingness to pay for adverse drug event regulatory actions. Pharmacoeconomics 29(11), 963-975 (2011)
- (2011) Pharmacoeconomics , vol.29 , Issue.11 , pp. 963-975
- Bouvy, J.¹ Weemers, J.² Schellekens, H.³ Koopmanschap, M.⁴

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.